-
1.发明授权Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension 失效用于在液体悬液中控制释放莫维霉素的药物组合物
公开(公告)号：US5674533A
公开(公告)日：1997-10-07
申请号：US452435
申请日：1995-05-26
IPC分类号： A61K9/107 , A61K9/00 , A61K9/50 , A61K9/52 , A61K31/425 , A61K31/426 , A61K47/30 , A61K9/16
CPC分类号： A61K9/0095 , A61K31/426 , A61K9/5073
摘要： Disclosed are compositions and dosage forms containing moguisteine and having controlled release properties, methods for using such compositions and dosage forms and methods for making them.
摘要翻译： 公开了含有莫维霉素并具有控制释放性质的组合物和剂型，使用这些组合物的方法和剂型以及制备它们的方法。
-
公开(公告)号：US5527545A
公开(公告)日：1996-06-18
申请号：US165307
申请日：1993-12-10
CPC分类号： A61K9/0095 , A61K31/19 , A61K31/192 , A61K9/5073
摘要： Disclosed is a liquid-suspension controlled-release enteric-coated pharmaceutical formulation for the administration of naproxen, comprising (a) microgranules of naproxen and an excipient; (b) four successive coats of polymeric hydrophilic and hydrophobic materials, at least the innermost of said coats imparting controlled-release properties to said naproxen according to a predetermined release profile, and at least the outermost of said coats imparting resistance to dissolution in gastric fluids; and (c) a liquid administration vehicle. This composition enables the oral administration of naproxen as a single daily dose the adjustment of the dosage to a patient's requirements, and avoids detrimental effects of prolonged contact of naproxen with the gastric mucosa thus aiding oral intake and minimizing the drug's typical side effects.
摘要翻译： 公开了一种用于施用萘普生的液体 - 悬液控释肠溶衣制剂，其包含（a）萘普生微粒和赋形剂; （b）四个连续的聚合亲水和疏水材料的涂层，至少最内层的所述涂层根据预定的释放曲线赋予所述萘普生的控制释放性能，并且至少所述涂层的最外面赋予对胃液中溶解的抵抗力 ; 和（c）液体给药载体。 该组合物能够以单次日剂量口服给予萘普生，根据患者的要求调整剂量，并避免萘普生与胃粘膜长时间接触的有害作用，从而有助于口服摄入并使药物的典型副作用最小化。
-
3.发明授权Therapeutic compositions for intranasal administration which include KETOROLAC 失效用于鼻内给药的治疗组合物，其包括KETOROLAC公开(公告)号：US07476689B2
公开(公告)日：2009-01-13
申请号：US10792457
申请日：2004-03-02
IPC分类号： A61K31/407 , A61K9/72 , A61N9/08 , A61K31/74
CPC分类号： A61K31/40 , A61K9/0043 , Y10S514/947 , Y10S514/958
摘要： An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.
摘要翻译： 一种止痛/抗炎药物剂型，其包含有效量的选自外消旋5-苯甲酰基-2,3-二氢-1H-吡咯嗪-1-羧酸，其光学活性形式和药学上的活性成分 可接受的盐，与药学上可接受的赋形剂或稀释剂组合，所述剂型为鼻内给药剂型。
-
4.发明授权Therapeutic compositions for intranasal administration which include KETOROLAC 有权用于鼻内给药的治疗组合物，其包括KETOROLAC公开(公告)号：US07267827B2
公开(公告)日：2007-09-11
申请号：US09903665
申请日：2001-07-13
CPC分类号： A61K31/40 , A61K9/0043 , Y10S514/947 , Y10S514/958
摘要： An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.
摘要翻译： 一种镇痛/抗炎药物剂型，其包含有效量的选自外消旋5-苯甲酰基-2,3-二氢-1H-吡咯嗪-1-羧酸，其光学活性形式和药学上的活性成分 可接受的盐，与药学上可接受的赋形剂或稀释剂组合，所述剂型为鼻内给药剂型。
-
5.发明授权Therapeutic compositions for intranasal administration which include KETOROLAC® 失效用于鼻内给药的治疗组合物，其包括KETOROLAC（R）公开(公告)号：US06333044B1
公开(公告)日：2001-12-25
申请号：US08383707
申请日：1995-02-01
IPC分类号： A61K914
CPC分类号： A61K31/40 , A61K9/0043 , Y10S514/947 , Y10S514/958
摘要： An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.
摘要翻译： 一种镇痛/抗炎药物剂型，其包含有效量的选自外消旋5-苯甲酰基-2,3-二氢-1H-吡咯嗪-1-羧酸，其光学活性形式和药学上的活性成分 可接受的盐，与药学上可接受的赋形剂或稀释剂组合，所述剂型为鼻内给药剂型。
-
公开(公告)号：US5670171A
公开(公告)日：1997-09-23
申请号：US482092
申请日：1995-06-07
CPC分类号： A61K9/0095 , A61K31/19 , A61K31/192 , A61K9/5073
摘要： Disclosed is a liquid-suspension controlled-release enteric-coated pharmaceutical formulation for the administration of naproxen, comprising (a) microgranules of naproxen and an excipient; (b) four successive coats of polymeric hydrophilic and hydrophobic materials, at least the innermost of said coats imparting controlled-release properties to said naproxen according to a predetermined release profile, and at least the outermost of said coats imparting resistance to dissolution in gastric fluids; and (c) a liquid administration vehicle. This composition enables the oral administration of naproxen as a single daily dose the adjustment of the dosage to a patient's requirements, and avoids detrimental effects of prolonged contact of naproxen with the gastric mucosa thus aiding oral intake and minimizing the drug's typical side effects.
摘要翻译： 公开了一种用于施用萘普生的液体 - 悬液控释肠溶衣制剂，其包含（a）萘普生微粒和赋形剂; （b）四个连续的聚合亲水和疏水材料的涂层，至少最内层的所述涂层根据预定的释放曲线赋予所述萘普生的控制释放性能，并且至少所述涂层的最外面赋予对胃液中溶解的抵抗力 ; 和（c）液体给药载体。 该组合物能够以单次日剂量口服给予萘普生，根据患者的要求调整剂量，并避免萘普生与胃粘膜长时间接触的有害作用，从而有助于口服摄取，并使药物的典型副作用最小化。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.022 秒)
